Akari Therapeutics (AKTX) EBIT (2014 - 2026)
Akari Therapeutics' (AKTX) quarterly EBIT came in at -$15.8 million in Q1 2026, down 347.04% year-on-year from $6.4 million in Q1 2025, and down 388.32% quarter-over-quarter from -$3.2 million in Q4 2025.
Akari Therapeutics (AKTX) EBIT (2014 - 2026) Analysis & Trends
Akari Therapeutics has disclosed EBIT across 9 years of filings, most recently posting -$15.8 million for Q1 2026.
- EBIT for Q1 2026 came in at -$15.8 million, down 347.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.5 million (up 76.56% YoY), and the FY2025 annual result was -$17.3 million, up 20.18% from the prior year.
- EBIT came in at -$15.8 million for Q1 2026 at Akari Therapeutics, down from -$3.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$2.5 million in Q3 2023 to a low of -$112.0 million in Q4 2024.
- The 4-year median for EBIT is -$4.6 million (2023), against an average of -$13.7 million.
- Across the five-year window, EBIT sank 2100.12% in 2024 and surged 97.12% in 2025, its largest moves.
- Akari Therapeutics' EBIT stood at -$5.1 million in 2023, then tumbled by 2100.12% to -$112.0 million in 2024, then soared by 97.12% to -$3.2 million in 2025, then slumped by 388.32% to -$15.8 million in 2026.
- The last three EBIT figures came in at -$15.8 million (Q1 2026), -$3.2 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 642.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -3.23 Mn |
| Sep 30, 2025 | -7.40 Mn |
| Jun 30, 2025 | -3.12 Mn |
| Mar 31, 2025 | -3.53 Mn |
| Dec 31, 2024 | -111.99 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -7.45 Mn |
| Mar 31, 2024 | -5.99 Mn |
| Dec 31, 2023 | -5.09 Mn |
| Sep 30, 2023 | -2.51 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -4.59 Mn |
| Dec 31, 2020 | -6.90 Mn |
| Sep 30, 2020 | -246,883.00 |
| Jun 30, 2020 | -5.91 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -3.12 Mn |
| Jun 30, 2019 | -6.03 Mn |